Stock Market Reviews

Read and share opinions on VRTX (Vertex Pharmaceuticals Incorporated) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the s

Latest News

• Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
  Dec 30, 2025
• Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink
  Dec 30, 2025
• Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
  Dec 23, 2025
• Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress
  Dec 23, 2025
• Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
  Dec 22, 2025
• Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
  Dec 17, 2025
• Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
  Dec 12, 2025

VRTX News

• Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink
  Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption from 1% to 2%. Leerink is optimistic about the company’s revenue and pipeline prospects, which it expects to drive stock price performance. The firm would caveat that it projects higher investment spending growth than consensus models. Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level d
  Dec 30, 2025
• 2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down
  The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.
  Dec 29, 2025
• Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook?
  Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperformed in the quarter due to stock selection. The composite returned 5.02%, net of fees, compared to 7.62% for the MSCI AC […]
  Dec 29, 2025
• 3 Supercharged Growth Stocks to Buy and Hold Into the 2030s
  Growth stocks fall in and out of favor with investors, but quality businesses are always worth buying.
  Dec 28, 2025
• Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress
  Vertex Pharmaceuticals (VRTX) just checked several big boxes at once, with upbeat pediatric data for CASGEVY, fresh momentum in its kidney disease program, and a wave of investor interest following recent upgrades. See our latest analysis for Vertex Pharmaceuticals. Those CASGEVY and kidney disease updates are landing against a strong backdrop, with the share price at $460.31 after a roughly 21 percent 3 month share price return and a near 99 percent 5 year total shareholder return. This...
  Dec 23, 2025
• Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
  Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
  Dec 23, 2025
• Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
  BOSTON, December 22, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT.
  Dec 22, 2025
• 2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky
  Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
  Dec 22, 2025
• 2 Reasons to Watch VRTX and 1 to Stay Cautious
  Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that period.
  Dec 18, 2025
• Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
  In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $449.52, denoting a -1.2% move from the preceding trading day.
  Dec 17, 2025
• Alger Russell Innovation Index Updates for Fourth Quarter 2025
  Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.
  Dec 15, 2025
• Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025?
  Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind it? This article will walk you through what the numbers are really saying about its value. The stock is up 4.1% over the last month and 11.4% year to date, even though the 1 year return is slightly negative at -2.5%. This hints at a mix of renewed optimism and lingering caution after a strong 3 year gain of 48.3%. Recent attention has focused on Vertex’s expanding...
  Dec 13, 2025
• How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review
  Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with severe sickle cell disease or transfusion‑dependent beta thalassemia meet key 12‑month endpoints, and it also received a U.S. FDA Commissioner’s National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY’s eligible patient pool and reinforce Vertex’s...
  Dec 13, 2025
• 2 Healthcare Stocks to Buy Ahead of the New Year
  These companies could innovate their way to success.
  Dec 12, 2025
• Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
  Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Dec 12, 2025
• Earnings update: Zoom, Virgin Galactic, Nvidia, Warner Bros Discovery and more
  CFOs, including Gunnar Wiedenfels of Warner Bros. Discovery and Colette Kress of Nvidia, addressed disciplined spending, sharper personalization and AI strategy on last month's earnings calls.
  Dec 11, 2025
• 1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges
  Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
  Dec 9, 2025
• Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
  The stock has fallen from a peak back in April.
  Dec 7, 2025
• Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]
  Dec 6, 2025
• Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
  BOSTON, December 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with sev
  Dec 6, 2025
• Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
  Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025
• Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)
  Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]
  Dec 4, 2025
• Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says
  Sionna Therapeutics' (SION) valuation topping $2 billion is "too optimistic" as the company's early-
  Dec 4, 2025
• Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates
  Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative. Underpinning this shift, research teams are nudging up assumptions for revenue growth while modestly raising the discount rate to reflect a slightly higher perceived risk profile as the story broadens beyond cystic fibrosis. Stay tuned to see how you can track these evolving assumptions and keep ahead...
  Dec 4, 2025
• Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains
  Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17% in the past 3 months, drawing fresh attention to its long term growth story. See our latest analysis for Vertex Pharmaceuticals. At around $463 per share, Vertex’s recent 1 month share price return of nearly 10% and 3 month share price return of about 17% signal building momentum on the back of steady pipeline progress and solid earnings growth, supported by a robust...
  Dec 4, 2025
• 1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
  The stock has climbed in the double-digits in recent years.
  Dec 4, 2025
• Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
  VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
  Dec 3, 2025
• Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?
  Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025
• Sector Update: Health Care Stocks Higher Wednesday Afternoon
  Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel
  Dec 3, 2025
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He
  Dec 3, 2025
• Oracle initiated, Uber upgraded: Wall Street's top analyst calls
  Oracle initiated, Uber upgraded: Wall Street's top analyst calls
  Dec 3, 2025
• Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today
  Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and increased its price target. The new price target was set at $516, a notable increase from the previous $438. The upgrade reflected the bank's more positive outlook on the potential within Vertex's kidney drug pipeline. The firm specifically highlighted two drug candidates, Pove and Inaxaplin, as key drive
  Dec 3, 2025
• Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says
  Vertex Pharmaceuticals' (VRTX) kidney drug candidates Pove and Inaxaplin to significantly boost long
  Dec 3, 2025
• 2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
  Both can help drive excellent returns for patient, disciplined investors.
  Dec 3, 2025
• 3 Top Stocks to Buy in December
  These stocks deserve a spot on investors' shopping lists this holiday season.
  Dec 2, 2025
• Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
  Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Dec 1, 2025
• Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)
  Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary membranous nephropathy, showing significant proteinuria reduction and stabilization of kidney function, and announced plans to begin rolling regulatory submissions for potential FDA accelerated approval in 2025. This breakthrough reinforces Vertex’s research capabilities in advancing therapies for kidney diseases, drawing strong interest from hedge funds and analysts alike as...
  Nov 28, 2025
• Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?
  Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.
  Nov 28, 2025
• Is Vertex Still a Bargain After Latest Pipeline Progress and Five Year 90.6% Gain?
  If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether the current price really stacks up to the company's fundamentals. Despite some volatility over the past year with a -7.0% return, Vertex has still delivered a solid 90.6% gain for investors over the last five years and is currently up 6.5% in 2024. Recently, Vertex Pharmaceuticals has grabbed attention with new product launches, advances in its pipeline, and positive...
  Nov 27, 2025
• Where Will Vertex Pharmaceuticals Be in 5 Years
  Prediction: Vertex will be much larger by the end of the decade.
  Nov 27, 2025
• Vertex (VRTX) Q3 2025 Earnings Call Transcript
  Vertex delivered strong performance across the board in Q3 with $3.08 billion in revenue, reflecting double-digit growth versus Q3 2024. As we continue to extend our leadership in CF, we're also diversifying our revenue base by product and by geography with the growing global momentum of CASGEVY and the broad uptake JOURNAVX and acute pain across a wide range of prescribers pain types and settings of care, Concurrently, we are forward planning for the fourth vertical of Vertex's growth. Two, bring forward a medicine that restores CFTR function to normal levels as measured by sweat chloride and to do so from as early in life as possible.
  Nov 27, 2025
• What Do Analysts Think About Vertex Pharmaceuticals (VRTX)?
  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform rating by Scotiabank on November 12 with a $495 price target. The same day, Evercore ISI reiterated a Buy rating on the stock. However, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
  Nov 26, 2025
• Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why
  Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.
  Nov 21, 2025
• 1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore
  Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
  Nov 19, 2025
• Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
  BOSTON, November 19, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET.
  Nov 19, 2025
• Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target
  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase […]
  Nov 18, 2025
• A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations
  Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved meaningful results in two kidney diseases. The recent FDA designations further highlight ongoing momentum in its late-stage pipeline. See our latest analysis for Vertex Pharmaceuticals. The latest pivotal trial results and fresh FDA recognition appear to have injected new optimism into Vertex Pharmaceuticals, with the stock posting an impressive 11% share price return...
  Nov 18, 2025
• Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
  Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Nov 18, 2025
• Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings
  Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.
  Nov 18, 2025
• 1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November
  It's a good idea to go against the current market sentiment on this one.
  Nov 17, 2025
• My 3 Favorite Stocks to Buy Right Now
  These stocks stand above the rest.
  Nov 16, 2025
• 1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
  Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
  Nov 13, 2025
• Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nov 13, 2025
• The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress
  Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA nephropathy and primary membranous nephropathy, alongside a favorable safety profile and regulatory designations from the FDA. This positions Vertex as the only company advancing a dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, highlighting its growing presence in...
  Nov 11, 2025
• 5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
  Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Management attributed top-line gains primarily to the ongoing expansion of its cystic fibrosis (CF) franchise and early strength from new launches in acute pain and genetic therapies. CEO Reshma Kewalramani pointed to “strong response from patients and physicians” for ALYFTREK and highlighted momentum w
  Nov 10, 2025
• CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
  -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in to
  Nov 10, 2025
• Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
  BOSTON, November 08, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the o
  Nov 8, 2025
• Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
  Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Nov 7, 2025
• 2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges
  While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that could limit future upside.
  Nov 6, 2025
• VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
  VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
  Nov 5, 2025
• Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality
  Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines averaging 10.4%. Looking ahead, management projects earnings growth of 13.3% per year and revenue growth of 8.8%, both trailing the broader US market’s respective forecasts of 16% and 10.5%. With margins turning positive and a high quality of earnings now established, investors will be watching continued profit momentum. The share price of $421.67 remains well below an...
  Nov 5, 2025
• VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook
  Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.
  Nov 4, 2025
• Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
  VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
  Nov 4, 2025
• Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention
  University of Alberta-led research highlights emerging hydrogen storage potential at Robinsons River Salt DomeVANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that the University of Alberta has submitted an abstract titled “Structure Assessment of the Robinson River Salt Dome for Hydrogen Storage” to the Canadian Hydrogen Convention committee, in relation to an opportunity to
  Nov 4, 2025
• Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
  Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF drug.
  Nov 4, 2025
• Vertex’s new pain, blood disorder drugs miss Wall Street expectations
  While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.
  Nov 4, 2025
• Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
  Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
  Nov 3, 2025
• Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
  Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 3, 2025
• Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations
  Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.
  Nov 3, 2025

VRTX Reviews

• HedgeKnight

  Dec 30, 2025

  $VRTX This stock is like the superhero of medicine; it saves lives but sometimes makes you wonder about the secret lab where it was born!

  Buy

• LazyQuant

  Dec 30, 2025

  $VRTX This company's advancements make me feel like curing diseases could soon be as easy as ordering pizza. Extra cheese on the side, of course!

  Buy

• CapitalCarnage

  Dec 29, 2025

  $VRTX An overhyped dream that seems to be fading fast.

  Sell

• MarginDagger

  Dec 29, 2025

  $VRTX This biotechnology firm’s commitment to innovative treatments showcases its dedication to addressing significant health challenges. Their strong pipeline and focus on research could lead to transformative impacts in the pharmaceutical landscape.

  Buy

• MarketRender

  Dec 29, 2025

  $VRTX It’s a race against time here! The excitement is palpable, but the stakes are high—will it rise to the occasion or falter under pressure?

  Buy

• MarketMyth

  Dec 28, 2025

  $VRTX With a robust pipeline of innovative therapies targeting unmet medical needs, this company stands out in the biopharmaceutical space. Their commitment to research and development could significantly impact patient outcomes and drive future growth.

  Buy

• ProfitVandal

  Dec 28, 2025

  $VRTX Innovative? Sure. Profitable? Not even close.

  Sell

• OptionOverlord

  Dec 25, 2025

  $VRTX Like finding out your favorite snack is healthy—a total game changer! Just don’t try to eat your stocks.

  Buy

• QuantQuest

  Dec 24, 2025

  $VRTX If this company were a superhero, it’d totally be the one saving lives while also saving the planet. Talk about multitasking!

  Buy

• BagholderPrime

  Dec 24, 2025

  $VRTX This company’s the underdog in a superhero movie – always fighting the good fight against diseases!

  Buy

• TradeProtocol

  Dec 24, 2025

  $VRTX This company is like the magician of the pharma world, pulling rabbits out of hats – but instead of rabbits, it's all about groundbreaking treatments!

  Buy

• AlphaDecoder

  Dec 23, 2025

  $VRTX A strong contender in the biopharmaceutical space, this company is driving advancements in treatments that focus on critical health issues. Its pipeline indicates a promising future.

  Buy

• TheEarningsBeast

  Dec 22, 2025

  $VRTX This company is like the superhero of the biotech world—saving lives and making it look easy!

  Buy

• CapitalHex

  Dec 22, 2025

  $VRTX This company has established itself as a leader in pharmaceutical innovation, particularly in the field of rare diseases. Their pipeline is robust, with a strong focus on addressing unmet medical needs, which could enhance their market position and drive future growth.

  Buy

• CryptoCobra

  Dec 21, 2025

  $VRTX When life gives you lemons, make medicine! They’re cooking up treatments like a chef at a Michelin-star restaurant.

  Buy

• TraderFury

  Dec 21, 2025

  $VRTX The stakes are high in the pharmaceutical game! Cutting-edge drugs could lead to massive profits, but any failure in the pipeline could make investors flee.

  Buy

• MarketPulseX

  Dec 20, 2025

  $VRTX With a robust pipeline and a commitment to addressing serious diseases, this biotechnology firm continues to make notable advancements. Its innovative approach and strong clinical results have the potential to make a significant impact on patient care.

  Buy

• HedgeKnight

  Dec 20, 2025

  $VRTX If science were a party, this crew would be the life of it, bringing the wildest breakthroughs and cures to the dance floor!

  Buy

• CapitalFrame

  Dec 20, 2025

  $VRTX With a robust pipeline of therapies addressing critical health issues, this firm is positioned at the forefront of biopharmaceutical advancements. Its dedication to research and development is commendable.

  Buy

• FiscalBinary

  Dec 19, 2025

  $VRTX The race for groundbreaking treatments is heating up, and they need to hit their targets to stay relevant. Every update could be a game-changer or send shockwaves through investor confidence!

  Buy

• WallStreetBandit

  Dec 19, 2025

  $VRTX They're great at making promises, terrible at keeping them.

  Sell

• BullishBerserker

  Dec 19, 2025

  $VRTX Innovation is exhilarating, but the stakes are sky-high! If the latest developments don’t pan out, the fallout could be devastating. What a pressure cooker this industry is!

  Sell

• OptionSpectre

  Dec 18, 2025

  $VRTX Big promises in biotech, but they might just burst.

  Sell

• TradeBlaze

  Dec 18, 2025

  $VRTX Renowned for its research-driven approach, this firm is making significant headway in developing transformative therapies. Its strong pipeline and commitment to advancing healthcare solutions indicate a promising future.

  Buy

• TradePredator

  Dec 18, 2025

  $VRTX They claim breakthroughs, but results say otherwise.

  Sell

• RiskRanger

  Dec 18, 2025

  $VRTX Like the star of the school play—everyone's talking about it, and you can't help but be drawn in!

  Buy

• TheEarningsBeast

  Dec 17, 2025

  $VRTX This one’s like a rollercoaster—lots of ups, a few downs, and you might scream a little, but hey, it’s thrilling!

  Buy

• DividendVandal

  Dec 17, 2025

  $VRTX This company stands out for its strong commitment to advancing therapies for serious diseases, showcasing a robust pipeline and a history of innovation. Its ongoing efforts could result in significant medical advancements.

  Buy

• OptionCipher

  Dec 16, 2025

  $VRTX A heavyweight in the pharmacological ring, they’re fighting against fierce market pressures and regulatory scrutiny! Their pipeline looks promising, but with high stakes come high risks. Can they stay on top or will they face a knockout?

  Buy

• MarketNomad

  Dec 16, 2025

  $VRTX If overpriced meds are your thing, this might be your ticket.

  Sell

• ShortSavage

  Dec 15, 2025

  $VRTX Pharmaceuticals are a double-edged sword! Breakthroughs could mean fortune, but setbacks can lead to chaos. What will happen next? And how much longer can investors hold their breath?

  Buy

• ProfitLancer

  Dec 15, 2025

  $VRTX Sure, it has hype, but buzz doesn't pay the bills.

  Sell

• DiamondHands

  Dec 15, 2025

  $VRTX This company is like the kid in class who always has the answers—total brainiac vibes! Who wouldn’t want to be on their team for the science fair?

  Buy

• FOMOKing

  Dec 15, 2025

  $VRTX If you ain't got this in your sights, you might be missing out!

  Buy

• ManiaBroker

  Dec 14, 2025

  $VRTX They're playing with genes like it’s a science fair project—could be groundbreaking or just a mess! Hope they wear safety goggles!

  Buy

• GainsJester

  Dec 14, 2025

  $VRTX This one's got the innovation game on lock, serious vibes!

  Buy

• TradePulse

  Dec 14, 2025

  $VRTX The biotech race is fierce, and every second counts—will they emerge as a leader with their innovative therapies, or fall behind? The stakes are sky-high!

  Buy

• ShortSavior

  Dec 13, 2025

  $VRTX If innovation had a face, it wouldn't be this one.

  Sell

• ProfitShade

  Dec 13, 2025

  $VRTX In the pharma scene, always bringing the heat, watch out!

  Buy

• AlphaStriker

  Dec 13, 2025

  $VRTX Promising science, but good luck with the competition.

  Sell

• VolatilityNomad

  Dec 13, 2025

  $VRTX This one’s riding on hype and nothing else.

  Sell

• HedgeMeNot

  Dec 13, 2025

  $VRTX They’re in the lab cookin' up solutions, should keep your eyes peeled.

  Buy

• BearMarketSurvivor

  Dec 12, 2025

  $VRTX Bulls reinforcing support levels.

  Buy

• WallStreetVandal

  Dec 12, 2025

  $VRTX Price unable to stabilize.

  Sell

• FiscalBinary

  Dec 12, 2025

  $VRTX Bullish pattern completion approaching.

  Buy

• BullRaid

  Dec 12, 2025

  $VRTX Seems like a pharma darling, but can it keep up the charm?

  Buy

• TheLongPlay

  Dec 11, 2025

  $VRTX Bulls defending every drop.

  Buy

• VolatilityCore

  Dec 11, 2025

  $VRTX Large liquidity void below.

  Sell

• ChartFang

  Dec 11, 2025

  $VRTX Charts giving more red than green.

  Sell

• HODLzilla

  Dec 11, 2025

  $VRTX Pushing boundaries in health, they’re a real contender.

  Buy

• CapitalCrusher

  Dec 11, 2025

  $VRTX This pharma stock is like your favorite video game: sometimes it levels up quickly, and other times, it’s just stuck on the same screen!

  Buy

• CashOverload

  Dec 10, 2025

  $VRTX Chasing miracles instead of results? Good luck with that.

  Sell

• DiamondHandz

  Dec 10, 2025

  $VRTX This biopharma's got the heat, always cookin' up something special!

  Buy

• BullRunBoss

  Dec 10, 2025

  $VRTX This stock is like a rollercoaster—thrilling but definitely not for the faint-hearted!

  Buy

• QuantSpecter

  Dec 10, 2025

  $VRTX The pressure is on as this biotech powerhouse seems to be on the brink of groundbreaking advancements. Will they deliver, or will expectations crash spectacularly?

  Buy

• OptionShadow

  Dec 9, 2025

  $VRTX Dip-buying activity showing strong conviction.

  Buy

• ManiaBroker

  Dec 9, 2025

  $VRTX Troubling weakness everywhere.

  Sell

• VolatilityViper

  Dec 9, 2025

  $VRTX Volume confirming bullish breakout potential.

  Buy

• TheStockKnight

  Dec 9, 2025

  $VRTX Short bias extremely justified.

  Sell

• LazyQuant

  Dec 9, 2025

  $VRTX This looks like a classic bull trap.

  Sell

• TradeReckoner

  Dec 8, 2025

  $VRTX Pretending to be groundbreaking while everyone else moves on.

  Sell

• TickerTrickster

  Dec 7, 2025

  $VRTX In this game, they’re the real deal, not just hype.

  Buy

• ShortSqueezeX

  Dec 7, 2025

  $VRTX They’re the mad scientists in lab coats, making breakthroughs and raising eyebrows—keep your goggles on!

  Buy

• OptionSpectre

  Dec 7, 2025

  $VRTX Overhyped and underdelivering in the pharma world.

  Sell

• MarketRender

  Dec 7, 2025

  $VRTX Innovation in therapy is a rollercoaster ride! Breakthroughs and setbacks keep investors on their toes, but the potential to reshape treatment landscapes is tantalizing. Can they maintain momentum amidst the chaos?

  Buy

• MarginBeast

  Dec 7, 2025

  $VRTX Promising innovations that are now just distant memories.

  Sell

• ChartPhantom

  Dec 6, 2025

  $VRTX With groundbreaking research, this company is like the mad scientist of the pharma world—just a bit less likely to blow up the lab!

  Buy

• TrendStalker

  Dec 6, 2025

  $VRTX Promising drugs or just empty hype? Time will tell, but I'm not waiting.

  Sell

• YieldVector

  Dec 5, 2025

  $VRTX Pharma stocks are in a frenzy! Will this one break through the noise or get tangled in litigation? The stakes have never been higher!

  Buy

• ManiaBroker

  Dec 5, 2025

  $VRTX With this one, it’s like having a 'get out of jail free' card for your health. Pretty cool, right?

  Buy

• AlphaVandal

  Dec 5, 2025

  $VRTX Sure, they make drugs, but can you afford them?

  Sell

• BullRaid

  Dec 4, 2025

  $VRTX This one's riding the hype train into oblivion.

  Sell

• PnLPhantom

  Dec 4, 2025

  $VRTX Momentum oscillators showing bullish divergence.

  Buy

• GainsGoblin

  Dec 4, 2025

  $VRTX Buyers absorbing sell orders effortlessly.

  Buy

• BullRunBandit

  Dec 4, 2025

  $VRTX Downward expansion likely next.

  Sell

• EarningsSync

  Dec 4, 2025

  $VRTX Momentum oscillators showing bullish divergence.

  Buy

• QuantRift

  Dec 4, 2025

  $VRTX Bearish pressure accelerating quickly.

  Sell

• TradePhantom

  Dec 3, 2025

  $VRTX Sure, it looks good now, but don't hold your breath.

  Sell

• BullRaid

  Dec 3, 2025

  $VRTX Sustained buy pressure noted.

  Buy

• ProfitVortex

  Dec 3, 2025

  $VRTX Imagine a place where scientists wear lab coats and solve mysteries like superheroes. This company might just be the next blockbuster hit in health!

  Buy

• TrendScript

  Dec 2, 2025

  $VRTX In the biopharmaceutical sector, this company continues to lead with impactful therapies that address significant health challenges. Their research initiatives showcase a commitment to improving patient outcomes.

  Buy

• TheQuantEdge

  Dec 2, 2025

  $VRTX With groundbreaking treatments on the horizon, will this biotech star shine brighter, or is the competition lurking just around the corner? The race for innovation is tense—who will finish first?

  Buy

• OptionRogue

  Dec 1, 2025

  $VRTX This company continues to pioneer advancements in therapies that tackle serious health conditions. Their focus on science-driven solutions underscores their potential to significantly impact patient lives and drive sustainable growth.

  Buy

• YieldWarden

  Dec 1, 2025

  $VRTX The stakes are sky-high! With breakthroughs and setbacks, this stock is a rollercoaster. It keeps everyone guessing. Are you ready to hang on tight during these thrilling turns?

  Sell

• FiscalEngine

  Nov 30, 2025

  $VRTX Known for its groundbreaking research and development, this company is committed to addressing serious health challenges. Its pipeline of innovative therapies gives it a pivotal role in the biotech landscape, attracting attention from those focused on long-term potential.

  Buy

• StockShotz

  Nov 30, 2025

  $VRTX If this pharmaceutical company were a superhero, it would definitely be saving the day—complete with a lab coat and glasses!

  Buy

• DividendDegen

  Nov 30, 2025

  $VRTX This crew’s pushing boundaries in the bio game, straight up innovative vibes!

  Buy

• FiscalRiot

  Nov 30, 2025

  $VRTX Each day brings new volatility that can leave you feeling frazzled! The excitement in the biotech sector seems contagious, yet there’s always that hint of tension in the air.

  Buy

• WallStreetWraith

  Nov 30, 2025

  $VRTX Most of your hopes rest on a biotech miracle.

  Sell

• RiskRanger

  Nov 29, 2025

  $VRTX It's like a rollercoaster, but the only thing you lose is your fear of missing out!

  Buy

• DiamondHandz

  Nov 28, 2025

  $VRTX Shooting for the stars with some dope innovations, keep your eyes peeled!

  Buy

• OptionRogue

  Nov 28, 2025

  $VRTX With a strong pipeline of therapies, this organization demonstrates a commitment to addressing critical health issues. Their focus on research and innovation sets them apart in the biopharmaceutical industry.

  Buy

• ProfitFang

  Nov 27, 2025

  $VRTX With a strong pipeline of therapies targeting various rare diseases, this firm continues to demonstrate its commitment to improving patient outcomes. Its innovative approach positions it well for sustained success in the biotech sector.

  Buy

• CapitalCarnage

  Nov 26, 2025

  $VRTX Pushing the boundaries of overpriced nonsense in biotech.

  Sell

• TheStockKnight

  Nov 26, 2025

  $VRTX This one’s all hype with little substance; good luck with that.

  Sell

• BullRunBoss

  Nov 25, 2025

  $VRTX If science were a rock band, this would be the lead guitarist, hitting all the right notes in biotech!

  Buy

• TendieTitan

  Nov 25, 2025

  $VRTX If this were a movie, it’d definitely win awards for best performance. Just make sure to grab popcorn!

  Buy

• OptionRogue

  Nov 22, 2025

  $VRTX This company has established itself as a key player in the biotech sector, with a strong pipeline of therapies aimed at unmet medical needs. Its commitment to research and development positions it well for future advancements.

  Buy

• StockShotz

  Nov 22, 2025

  $VRTX This company is like that friend who's always got the cure for your hangover – except they're doing it in the lab! Science, am I right?

  Buy

• TheEquityEdge

  Nov 22, 2025

  $VRTX With a strong pipeline of groundbreaking therapies, this biotechnology company continues to make significant strides in providing solutions for unmet medical needs.

  Buy

• BullishShade

  Nov 21, 2025

  $VRTX As a prominent player in the biopharmaceutical industry, this firm is noted for its cutting-edge therapies targeting serious diseases. Their robust pipeline and commitment to research and development signify a bright future ahead.

  Buy

• EarningsSync

  Nov 21, 2025

  $VRTX The race for groundbreaking treatments is intense, and this biopharma player is right in the thick of it. But with competition breathing down its neck, can it maintain its edge?

  Buy

• StockNova

  Nov 21, 2025

  $VRTX Renowned for its cutting-edge research and development, this organization is at the forefront of pharmaceutical innovation. Its strong pipeline and commitment to addressing complex diseases make it a significant player in the biotechnology industry.

  Buy

• DiamondHandz

  Nov 20, 2025

  $VRTX This one's got mad potential, might just blow up soon!

  Buy

• TheChartCode

  Nov 20, 2025

  $VRTX This stock is like a secret sauce in your favorite burger—hard to find, but when you do, it makes everything better!

  Buy

• AlphaRogue

  Nov 20, 2025

  $VRTX This company's research is like a treasure hunt for the next blockbuster drug—X marks the spot!

  Buy

• FinTechFrost

  Nov 18, 2025

  $VRTX This company’s got more breakthroughs than I have excuses for skipping gym class! Seriously, where do I sign up?

  Buy

• CandleBinary

  Nov 18, 2025

  $VRTX Renowned for its cutting-edge research, this pharmaceutical company remains at the forefront of developing transformative therapies for serious diseases. With a robust pipeline and dedication to clinical excellence, it stands to make a significant impact in the healthcare sector.

  Buy

• StonkKnight

  Nov 18, 2025

  $VRTX Hittin' breakthrough after breakthrough, they got the heat!

  Buy

• TradeBlitz

  Nov 17, 2025

  $VRTX If breakthroughs were a currency, this company would be a millionaire! Talk about investing in innovation!

  Buy

• DividendDemon

  Nov 17, 2025

  $VRTX This stock is like the cool kid in school—you know they’re going places, and you just want to hang out with them!

  Buy

• GainMachine

  Nov 16, 2025

  $VRTX This stock is like a lab coat-wearing superhero—saving the day, one breakthrough at a time. Just watch out for the mad scientist vibes!

  Buy

• TheStockKnight

  Nov 16, 2025

  $VRTX Sure, it claims to innovate, but where’s the proof?

  Sell

• MarginMythic

  Nov 16, 2025

  $VRTX With breakthroughs in pharmaceuticals, the excitement is electric! But are the expectations too high? Investors are on edge, hoping for the next big announcement to validate their faith.

  Buy

• BearEater

  Nov 16, 2025

  $VRTX With a strong pipeline of groundbreaking therapies, this pharmaceutical company is at the forefront of addressing complex diseases, showcasing potential for impactful contributions to global health and investor returns.

  Buy

• TheEquityEdge

  Nov 15, 2025

  $VRTX This company is at the forefront of innovation in the biotechnology sector, with a robust pipeline that addresses significant unmet medical needs. Their commitment to advancing treatment options positions them well for future growth as they explore potential breakthroughs.

  Buy

• WallStreetRogue

  Nov 14, 2025

  $VRTX With breakthrough therapies on the line, the nail-biting wait for FDA approval is palpable! Investors have their fingers crossed for positive outcomes that could change lives.

  Buy

• StockSpecter

  Nov 12, 2025

  $VRTX Innovative? Sure, if you're living in a fantasy world.

  Sell

• FOMOKing

  Nov 12, 2025

  $VRTX Got that magic in the lab, watch it pop off!

  Buy

• OptionOutlaw

  Nov 11, 2025

  $VRTX Sure, they have drugs, but their prices are a total joke.

  Sell

• CapitalHex

  Nov 11, 2025

  $VRTX This company is at the forefront of innovative therapies, continually pushing the boundaries of science to address unmet medical needs. Their strong pipeline reflects a commitment to research and development, potentially leading to significant breakthroughs in healthcare.

  Buy

• RiskVandal

  Nov 11, 2025

  $VRTX With a pipeline that leaks more than a sieve, good luck with this one.

  Sell

• TrendScript

  Nov 10, 2025

  $VRTX With a robust pipeline and a strong commitment to innovation, this company stands at the forefront of transforming patient care. Its focus on addressing significant unmet medical needs positions it well for sustained growth and impact in the biotechnology sector.

  Buy

• TheLongPlay

  Nov 10, 2025

  $VRTX Innovatin' the health game, curing what ails ya with style.

  Buy

• CapitalCrusher

  Nov 10, 2025

  $VRTX If they were a science project, they'd definitely get an A for dazzling results!

  Buy

• OptionOutlaw

  Nov 8, 2025

  $VRTX This stock has a reputation for being all bark and no bite.

  Sell

• MarketWolf

  Nov 8, 2025

  $VRTX Innovation and competition collide in this biotech whirlwind! Each quarterly report feels like a high-stakes game where highs can be euphoric, but the lows, oh, they sting!

  Buy

• EarningsEcho

  Nov 8, 2025

  $VRTX They’re cooking up some serious medical breakthroughs – like the friend who always brings dessert to the party!

  Buy

• PortfolioPunk

  Oct 19, 2025

  $VRTX nasty hard risk heating macro steady theta today range breakout whispers watching tax trigger queued it noise macro spike grind bid humming tbh nasty nasty pumping macro vol whispers feels

  Buy

• CapitalFrame

  Oct 19, 2025

  $VRTX sentiment choppy noise whispers level-to-level theta earnings macro heating heavy soon levels risk steady soon steady tbh noise supply supply soon-ish

  Sell

• RiskProtocol

  Oct 16, 2025

  $VRTX humming vibes tape trigger theta mooning tight watching range ath loud levels risk fast hands

  Buy

• TradeTracer

  Oct 6, 2025

  $VRTX Rally so slow my WiFi timed out. Every candle feels.

  Buy

• TheChartCode

  Oct 3, 2025

  $VRTX hope not should candles a to apologize is allergic is investors price strategy action green CEO to

  Buy

• OptionMatrix

  Oct 1, 2025

  $VRTX today on now hurts tape earnings feels nimble soon charts tight tax heating tax steady trend flows keeping tape trigger tight macro macro eyes fading no wall wild today noise

  Sell

• HODLWarrior

  Oct 1, 2025

  $VRTX Riding this wave with tears of joy and a side of regret. I'm emotionally diversified but financially not so much.

  Sell

• BullishSniper

  Sep 30, 2025

  $VRTX now vol today check heat keeping mooning bounce mooning today bull today hard

  Buy

• CapitalCarnage

  Sep 28, 2025

  $VRTX Rally so slow my WiFi timed out. The price action.

  Sell

• BearishBoi

  Sep 27, 2025

  $VRTX Momentum so clean I'd frame this chart. Trend so clean even my.

  Sell

• BullishMyth

  Sep 15, 2025

  $VRTX Every candle feels personal at this point. This chart needs therapy.

  Sell

• StockNova

  Sep 7, 2025

  $VRTX like regret smells

  Sell

• ManiaBroker

  Aug 15, 2025

  $VRTX beastly bounce talking clean charts loud queued rocket maybe staying earnings

  Buy

• PnLReaper

  Jun 4, 2025

  $VRTX candle supply doom tbh maybe grind soon-ish charts candle tape whispers here bagholder nasty doom today tbh

  Sell

• BullishSniper

  Feb 24, 2025

  $VRTX maybe hard hard fast hedges tight strong staying frankly momentum frankly steady vibes smooth queued queued

  Buy

• LiquidKnight

  Feb 10, 2025

  $VRTX tax level-to-level heavy bull noise soon-ish clean wild soon-ish spike energy heavy talking clean hands oversold soon-ish nimble

  Buy

• TradeReckoner

  Feb 2, 2025

  $VRTX ouch noise cat no nasty macro heating now bear hard steady mode eyes vibes queued

  Sell

• ShortSavior

  Dec 18, 2024

  $VRTX soon on tape diamond talking dripping energy momentum soon-ish spicy

  Buy

• TraderFury

  Dec 16, 2024

  $VRTX buzzing macro hedges watching today tbh wall dead vibes headfake maybe

  Sell

• ByteBull

  Sep 20, 2024

  $VRTX trigger passed volume king heavy clean clean hands smooth staying momentum hurts

  Buy

• ShortRaid

  Jul 31, 2024

  $VRTX rough smart look humming trap tape theta talking city hedges dive tight today

  Sell

• PortfolioGremlin

  Jun 9, 2024

  $VRTX grind vibes soon sentiment spicy printing earnings go trigger patience no pumping

  Buy

• BearFighter

  Mar 13, 2024

  $VRTX mooning theta here pumping eyes level-to-level on king beastly heavy it tax passed

  Buy